Abstract

The infectious disease from Coronavirus Disease 2019, or COVID-19, has quickly spread world-wide since 2019. Therapies for managing COVID-19 have yet to be confirmed as medication for the severe sickness that the disease may cause. This study aimed to review the previous research of the efficacy of trial therapy and treatment to the patients in the hospital with COVID-19. Using PRISMA guidelines as a method for conducting a systematic literature review, a total of 67 articles were collected from several online journal databases. Various therapies were found that are effective in the treatment and management of COVID-19. In accordance with the inclusion and exclusion criteria of this study, a total of 8 articles were selected. The study showed that several therapies are effective in managing the severe illness, can be used as COVID-19 treatment. Combination of medicine have shown the effectiveness of clinical improvements and recovery rate in a short time compared to single medicine. Nevertheless, further study into effective therapies for COVID-19 must be continued to find the best therapy and treatment.

References

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease- 2019 (COVID-19): the epidemic and the challenges. International Journal of Antimicrobial Agents. 2020; 55 (3): 105924. 2. Kumar V, Jung YS, Liang PH. Anti-SARS coronavirus agents: a patent review (2008-present). Expert Opinion Therapeutic Patents. 2013; 23 (10): 1337–48. 3. Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. International Journal of Antimicrobial Agents. 2020; 155 (6): 105948. 4. World Health Organization. Coronavirus Disease (COVID-19): situation reports; 2020. 5. Kementrian Kesehatan Indonesia. Situasi terkini perkembangan coro - navirus disease (COVID-19) 3 Juni 2020. covid-19.kemkes.go.id; May 2020 . 6. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. 2020; 109: 102433. 7. Liu C, Zhou Q, Li Y, Garner L V, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and Vaccines for COVID-19 and related human coronavirus diseases. ACS Central Science. 2020; 6 (3): 315–31. 8. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A fami - lial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395 (10223): 514–23. 9. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061–9. 10. Chen C, Qi F, Shi K, Li Y, Li J, Chen Y, et al. Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 Pneumonia; Preprints 2020 (February):1–6. 11. Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A, Hershan AA, Kamal MA, et al. Therapeutic management of patients with COVID- 19: a systematic review. Infectio Prevention Practice. 2020; 2 (3): 100061. 12. Beauchet O, Dubost V, Herrmann FR, Kressig RW. Stride-to-stride variability while backward counting among healthy young adults. Journal of Neuroengineering and Rehabilitation. 2005; 2 (1): 26. 13. Tekelab T, Akibu M, Tagesse N, Tilhaun T, Yohanes Y. Neonatal mortality in Ethiopia: a protocol for systematic review and meta-analysis. Systematic Reviews. 2019; 8: 103. 14. Fakultas Kesehatan Masyarakat Universitas Indonesia. Writing a protocol (background and objective); 2018. 15. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine. 2020; 382: 1787-99. 16. Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020; 81 (1): e21-3. 17. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. Available online March 18, 2020. 18. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID- 19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020; 56 (1): 105949. 19. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus Disease 2019: a retrospective cohort study. Journal of Infect. 2020; 81 (1): e1-5. 20. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. medRxiv; 2020. 21. Liu K, Chen Y, Wu D, Lin R, Wang Z, Pan L. Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19. Complement Theraphies in Clinical Practice. 2020; 39: 101132. 22. Asyary A, Veruswati M. Sunlight exposure increased Covid-19 recovery rates: a study in the central pandemic area of Indonesia. Science of The Total Environment; 2020: 729: 139016. 23. Rajeswari S and Reddy NS. Efficacy of progressive muscle relaxation on pregnancy outcome among anxious Indian primi mothers. Iran Journal of Nursing and Midwifery Research. 2020; 25 (1): 23-30. 24. Ferendiuk E, Biegańska JM, Kazana P, Pihut M. Progressive muscle relaxation according to Jacobson in treatment of the patients with temporomandibular joint disorders. Folia Medica Cracoviensia. 2019; 59 (3): 113-22. 25. Slusky DJG, Zeckhauser RJ. Sunlight and protection against influenza. National Bureu Of Economic Research: NBER Working Paper Series. 2018; 1–34. 26. World Health Organization. Off-label use of medicines for COVID-19; March 2020. 27. Universitas Indonesia. Tim FIK UI dan IPB temukan kandidat pencegahan virus corona. www.ui.ac.id; 2020.

Download

Share

COinS